Alan M. Garber - Mar 21, 2024 Form 4 Insider Report for EXELIXIS, INC. (EXEL)

Role
Director
Signature
/s/ Nina Ayer, Attorney in Fact
Stock symbol
EXEL
Transactions as of
Mar 21, 2024
Transactions value $
-$1,393
Form type
4
Date filed
3/25/2024, 07:31 PM
Previous filing
Jun 2, 2023
Next filing
May 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EXEL Common Stock Options Exercise $460K +23.5K +74.77% $19.57 54.9K Mar 21, 2024 Direct
transaction EXEL Common Stock Sale -$461K -19.2K -34.98% $24.01 35.7K Mar 21, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EXEL Option (right to buy) Options Exercise $0 -23.5K -100% $0.00* 0 Mar 21, 2024 Common Stock 23.5K $19.57 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 8, 2023.
F2 Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $24.00 to $24.01. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.
F3 The option, representing the right to purchase a total of 23,491 shares of Exelixis, Inc. common stock became fully exercisable on May 25, 2017.